MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/clinem/dgad654

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2024

Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis.

Samnani Sunil, Cenzer Irena, Kline Gregory A, Lee Sei J, Hundemer Gregory L, McClurg Caitlin, Pasieka Janice L, Boscardin W John, Ronksley Paul E, Leung Alexander A

МетаанализСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

CONTEXT: Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, but the comparative outcomes of targeted treatment remain unclear.

OBJECTIVE

To compare the clinical outcomes in patients treated for primary aldosteronism over time.

METHODS

Medline and EMBASE were searched. Original studies reporting the incidence of mortality, major adverse cardiovascular outcomes (MACE), progression to chronic kidney disease, or diabetes following adrenalectomy vs medical therapy were selected. Two reviewers independently abstracted data and assessed study quality. Standard meta-analyses were conducted using random-effects models to estimate relative differences. Time to benefit meta-analyses were conducted by fitting Weibull survival curves to estimate absolute risk differences and pooled using random-effects models.

RESULTS

15 541 patients (16 studies) with PA were included. Surgery was consistently associated with an overall lower risk of death (hazard ratio [HR] 0.34, 95% CI 0.22-0.54) and MACE (HR 0.55, 95% CI 0.36-0.84) compared with medical therapy. Surgery was associated with a significantly lower risk of hospitalization for heart failure (HR 0.48 95% CI 0.34-0.70) and progression to chronic kidney disease (HR 0.62 95% CI 0.39-0.98), and nonsignificant reductions in myocardial infarction and stroke. In absolute terms, 200 patients would need to be treated with surgery instead of medical therapy to prevent 1 death after 12.3 (95% CI 3.1-48.7) months.

CONCLUSION

Surgery is associated with lower all-cause mortality and MACE than medical therapy for PA. For most patients, the long-term surgical benefits outweigh the short-term perioperative risks.

Для цитирования: Samnani Sunil, Cenzer Irena, Kline Gregory A, Lee Sei J, Hundemer Gregory L, McClurg Caitlin, Pasieka Janice L, Boscardin W John, Ronksley Paul E, Leung Alexander A. Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis.. The Journal of clinical endocrinology and metabolism. 2024. DOI: 10.1210/clinem/dgad654.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.